The Effect Of Anti-Hepatitis B Virus Therapy On The Prognosis Of HBV-Related BCLC-C Stage Hepatocellular Carcinoma Patients Undergoing Surgical Resection

Objective: To study the impact of HBV-related BCLC-C stage hepatocellular carcinoma patients receiving anti-hepatitis B virus therapy on the prognosis.Methods: A retrospective analysis of 250 patients with HBV-related BCLC-C hepatocellular carcinoma who underwent surgical treatment at the Affiliated Tumor Hospital of Guangxi Medical University from January 2006 to December 2016 was taken as the research object,according to whether the patients received long-term rules Antiviral treatment is divided into antiviral group(n=183)and non-antiviral group(n=67).Both groups of patients received surgical resection.In this study,the continuous variables did not meet the normal distribution through the normality test analysis,so the median and interquartile range were used for statistical description,the Mann-Whitney test was used,and the count data was compared using the chi-square test or Fisher exact probability method Differences.Kaplan-Meier method and Log-rank test were used for survival analysis of the two groups.For gender,age,complete tumor envelope(yes/no),regular resection(yes/no),number of tumors(single/multiple),primary tumor size,prothrombin time,TBIL,ALB,ALT,AST,ALP,GGT,anti-virus(yes/no)and other factors using log-rank test for single factor analysis of survival rate,Log-rank single factor analysis results have statistically significant factors into the Cox risk proportional model,multi-factor analysis screening Independent risk factors affecting the prognosis of patients with HBV-related BCLC-C liver cancer.Results:1.The median survival time of anti-virus group and non-anti-virus group were 16,10 months;the anti-virus group 1,3,and 5-year survival rates were55.7%,28.7%,and 20.7%,respectively,and the non-antivirus group 1,3.The 5-year survival rates were 40.3%,13.8%,and 11.9%,respectively,and the difference between the groups was statistically significant(P=0.005).2.The anti-virus group 1,3,and 5 years disease-free survival rates were28.7%,20.7%,and 19.4%,respectively,and the non-antiviral group 1,3,and 5years disease-free survival rates were 13.5%,11.6%,and 11.6%,respectively.The difference between the groups was statistically significant(P=0.013).3.Single factor analysis showed that the factors related to the prognosis include the integrity of the envelope(yes/no),the number of tumors(single/multiple),AST and anti-virus(yes/no).4.Cox multivariate analysis also showed that incomplete envelope,multiple tumors,AST and no antiviral treatment were independent risk factors that affected the prognosis of patients.Conclusions:1.Anti-hepatitis B virus therapy can improve the overall survival rate and relapse-free survival rate of patients with HBV-related BCLC-C stage hepatocellular carcinoma after surgery.2.Incomplete envelope,multiple tumors,AST and non-antiviral therapy are independent risk factors that affect the prognosis of patients with HBV-related BCLC-C stage hepatocellular carcinoma.